Alnylam Pharmaceuticals, Inc. (ALNY)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
+36.2% vs
Rating Accuracy
100.0% (4 of 4*)
Rating Return
+78.53% vs
Rating Accuracy
85.71% (6 of 7*)
FV Performance
FV Accuracy
12 Hits (171.43% Hit Rate)
FV Avg. Distance
-0.66%
FV Accuracy
25 Hits (192.31% Hit Rate)
FV Avg. Distance
+1.8%
FV Accuracy
27 Hits (108.0% Hit Rate)
FV Avg. Distance
+7.45%
FV Accuracy
34 Hits (69.39% Hit Rate)
FV Avg. Distance
+17.58%
About
CEO
John M. Maraganore
Employees
1,323
Industry
Endocrinology and Metabolism Biopharmaceuticals
Sector
Healthcare
Headquarters
Cambridge
Exchange
NASDAQ
Website
http://www.alnylam.comSummary Stats
Market Cap
17.7B
Revenue
880M
Net Income
-893M
EPS
-$7.49
Price-to-Earnings
-19.53
Price-to-Book
44.06
Debt-to-Equity
7.56
News
Analyst Ratings
Price targets projected by 23 analysts
High
$225.00
Average
$163.61
Low
$93.00
Ratings calculated by 24 analysts
Buy
16
Hold
8
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Above by $0.35
-$1.49 +19.0%
-1.84
-1.64
Up 9%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--